找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Clinical Pharmacology: Current Topics and Case Studies; Markus Müller (Professor and Head of Department) Book 20101st edition Springer-Ver

[復(fù)制鏈接]
樓主: monster
11#
發(fā)表于 2025-3-23 12:57:21 | 只看該作者
12#
發(fā)表于 2025-3-23 15:45:35 | 只看該作者
Current concepts of pharmacogenetics, pharmacogenomics, and the “druggable” genomelity can be translated into clinical practice. According to the current intriguing concepts of pharmacogenetics and pharmacogenomics, genetic information of individuals will be used to avoid “trial and error” scenarios during medication. Based on evidence from genomic testing, medicine is expected t
13#
發(fā)表于 2025-3-23 20:56:23 | 只看該作者
Biomarkerstifying biological markers as indicators for an underlying disease is an elementary concept in medicine. Since the beginning of the medical skill of healing, signs and symptoms have been interpreted by medical doctors and guided diagnosis and treatment of their patients. With the emergence of the bi
14#
發(fā)表于 2025-3-24 01:00:03 | 只看該作者
15#
發(fā)表于 2025-3-24 06:24:44 | 只看該作者
16#
發(fā)表于 2025-3-24 06:36:49 | 只看該作者
17#
發(fā)表于 2025-3-24 14:22:58 | 只看該作者
Safe Filler Injection Techniquesronic diseases and the determination of number of patients affected by a disease, the latter being a cornerstone of public healthcare and preventive medicine. Epidemiological research provides a methodological basis for determination of factors involved in disease progression and risk.
18#
發(fā)表于 2025-3-24 17:56:37 | 只看該作者
Epidemiology and bio statisticsronic diseases and the determination of number of patients affected by a disease, the latter being a cornerstone of public healthcare and preventive medicine. Epidemiological research provides a methodological basis for determination of factors involved in disease progression and risk.
19#
發(fā)表于 2025-3-24 22:53:03 | 只看該作者
Andrew M. Dearden,Michael D. Harrison, (b) clinically, by administering appropriate drug therapy to patients and (c) within a regulatory framework, to provide guidance on the risk/benefit ratio of drug candidates in drug development and drug reimbursement.
20#
發(fā)表于 2025-3-25 00:38:37 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 04:27
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
都昌县| 锦屏县| 响水县| 新昌县| 红安县| 五华县| 临沧市| 沙洋县| 曲阜市| 贵定县| 湖北省| 观塘区| 岐山县| 湘潭市| 奈曼旗| 房山区| 镇安县| 辉县市| 淳安县| 山阳县| 宝坻区| 屏东县| 江陵县| 东丽区| 玛曲县| 崇左市| 昆山市| 鲜城| 武胜县| 莱阳市| 柏乡县| 淮北市| 扎囊县| 富川| 泰顺县| 叙永县| 大安市| 西畴县| 金昌市| 渭南市| 墨江|